Professor John Cleland to give a Keynote Presentation on heart failure at the Georgia MedTech Innovation?Summit?2024
Nikolai "Nik" Nikitin, MD, PhD
President and Founder at Clinical Accelerator
The Georgia MedTech Innovation Summit is excited to announce that Professor John Cleland, one of the biggest names in clinical research into heart failure globally, will deliver a keynote presentation at the upcoming summit. The title of the presentation is “The problem with heart failure is…”
Professor Cleland is a Cardiologist and Director of the Robertson Centre for Biostatistics (Glasgow), an internationally renowned Clinical Trials Unit offering a complete service both to academia and industry for cardiovascular and metabolic disease. His main interest is heart failure, extending from epidemiology & prevention, to Phase II-IV trials and guidelines. Particular current interests include myocardial substrate, congestion & inflammation, telemonitoring & theranostics. He qualified from the University of Glasgow in 1977, completed training at St. Mary's & Hammersmith Hospitals (London) and was awarded a Senior Fellowship by the British Heart Foundation. He was appointed Prof. at the University of Hull and, in 2013, the National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College London. He founded the European Journal of Heart Failure. He is Past-Chair of the ESC Working Group on heart failure and British Society for Heart Failure
About the Georgia MedTech Innovation Summit:
The Georgia MedTech Innovation Summit aims to unite a dynamic community of companies, KOLs, physicians, investors, and strategists within the medtech sector who are interested in or are currently conducting early stage studies O-US. The event offers a platform for sharing knowledge, networking, and fostering collaboration in the development of groundbreaking medical technologies. Being a hybrid event, the summit will provide educational discussions with KOLs on technology advancements and strategically relevant talks for medtech companies and investors on efficient and successful execution of studies with an extra focus on regulatory and EFS (Early Feasibility Studies).